Stem Cells International / 2015 / Article / Fig 5

Research Article

Multiple Myeloma Patients at Various Cytogenetic Risks Benefit Differently from Autologous Stem Cell Transplantation as a Consolidation Therapy

Figure 5

Comparison of PFS in the patients of ASCT group and non-ASCT group in the intermediate-risk subgroup. The median PFS was 25.7 versus 15.1 months with no significant difference ().